uniQure (NASDAQ:QURE) Price Target Raised to $20.00 at Mizuho

uniQure (NASDAQ:QURE) had its price objective lifted by Mizuho from $7.00 to $20.00 in a report released on Thursday morning,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of uniQure in a report on Tuesday, December 10th. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. StockNews.com upgraded uniQure to a “sell” rating in a report on Wednesday, December 11th. Leerink Partners upped their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Finally, The Goldman Sachs Group increased their price target on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Price Performance

Shares of QURE stock traded up $0.89 during trading hours on Thursday, hitting $16.36. The stock had a trading volume of 193,269 shares, compared to its average volume of 1,651,960. uniQure has a one year low of $3.73 and a one year high of $17.71. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock’s 50-day moving average price is $7.90 and its two-hundred day moving average price is $6.68. The stock has a market capitalization of $797.44 million, a price-to-earnings ratio of -3.30 and a beta of 0.89.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Equities analysts forecast that uniQure will post -3.82 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.74% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC lifted its position in shares of uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares in the last quarter. Geode Capital Management LLC raised its holdings in uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after purchasing an additional 6,362 shares in the last quarter. American Century Companies Inc. raised its holdings in uniQure by 14.6% during the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 8,642 shares in the last quarter. Finally, RTW Investments LP purchased a new position in uniQure during the third quarter worth about $49,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.